RT Journal Article
SR Electronic
T1 International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 265
OP 269
DO 10.1124/pr.54.2.265
VO 54
IS 2
A1 Chun, Jerold
A1 Goetzl, Edward J.
A1 Hla, Timothy
A1 Igarashi, Yasuyuki
A1 Lynch, Kevin R.
A1 Moolenaar, Wouter
A1 Pyne, Susan
A1 Tigyi, Gabor
YR 2002
UL http://pharmrev.aspetjournals.org/content/54/2/265.abstract
AB The lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are now recognized as important extracellular signaling molecules. These lipid mediators are pleiotropic; among the most common cellular responses are mitogenesis, cell survival (anti-apoptosis), inhibition of adenylyl cyclase and calcium mobilization. Physiologic events associated with these mediators include platelet aggregation, vasopressor activity, wound healing, immune modulation, and angiogenesis. Many of the actions of LPA and S1P are mediated through a set of eight G protein-coupled receptors. Five of these are S1P-prefering while the remaining three are LPA receptors. These receptors are expressed widely and in aggregate signal through a variety of heterotrimeric G proteins. The lysophospholipid receptor family is referred to commonly as the “Edg” group (e.g., Edg-1, Edg-2, etc.). Herein, the molecular pharmacology of the lysophospholipid receptors is reviewed briefly, and a rational nomenclature for LPA and S1P receptors that is consistent with the International Union of Pharmacology guidelines is proposed.